ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
QbD assisted development of hyaluronic acid and TPGS incorporated DOX liposome(s): in vitro assessment of cytotoxicity, uptake, ROS, and NF-κB potential on MDA-MB-231 cells.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This work aimed to develop Doxorubicin (DOX), D‑alpha‑tocopheryl polyethylene glycol 1000 succinate (TPGS), and hyaluronic acid (HA) liposomal delivery system using the Quality by Design (QbD) methodology. Developed liposomal formulations show sustained release behaviour as compared to free DOX (96.7 ± 1.81% release in 12 h), as indicated by the release kinetics metrics (82.8 ± 2.82% & 69.8 ± 2.25% releases in 72 h of HA-DOX-TPGS-LIPO and DOX-TPGS-LIPO respectively). In vitro cytotoxicity by MTT assay on MDA-MB-231 and MCF-7 breast cancer cells demonstrated that HA-DOX-TPGS-LIPO had significantly higher cytotoxicity and a clear synergistic impact over free drug or DOX-TPGS-LIPO respectively. Higher cell internalization of HA-DOX-TPGS-LIPO was seen in an in vitro cellular uptake assay in contrast to free drug and DOX-TPGS-LIPO investigated by FACS analysis. ROS production was also assessed using 2', 7'-Dichlorofluorescin diacetates (DCFDA) in the FACS study. Upon treatment with HA-DOX-TPGS-LIPO, triple-negative breast cancer (TNBC) cells showed a higher ROS generation than free DOX and DOX-TPGS-LIPO. Moreover, the expression of the NF-κB protein was also analyzed as a possible substitute mechanism for apoptosis. Free DOX treatment resulted in the maximum expression of NF-κB protein, whereas the HA-DOX-TPGS-LIPO formulation showed the minimum expression of NF-κB protein at the same concentration of DOX-TPGS-LIPO. The study suggested that HA-tethered developed liposomal formulation could be an effective tumor treatment and may be a valuable targeted nanocarrier.
Indexed as
Identifiers
40310527What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.